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This study examines behavioural changes brought about by two interventions introduced to 
lower the incidence of cervical cancer in Australia. The first intervention is a media 
campaign promoting regular screening behaviour to women. The second intervention is a 
vaccination program providing a free HPV vaccine, Gardasil, to young women launched in 
the same period. The results using data from discrete choice experiments find that in 
general, given individual characteristics, the interventions have minor impact on how 
women value screening attributes. The interventions however alter women’s inherent taste 
for screening. Unexpectedly, willingness to screen is generally lower post-interventions. 
The reason for this trend appears to be related to HPV events. For instance, the reduction in 
screening participation is particularly marked among young women who are eligible for the 
vaccination program. There is also a larger aversion towards testing among women who 
gained information on HPV facts and HPV-related measures. Thus, in the face of HPV 
innovations, screening promotions need to account for these factors. A simulation exercise 
is then performed to assess the plausibility of several strategies to increase the screening 
rate. The results nominate supply-side policies, in particular those targeted to health 
providers, as the most effective strategy.  
Introduction 
 
Cervical cancer is one of the most preventable forms of cancer, yet it remains the second 
most common women’s cancer worldwide (Parkin, 2005). In Australia, about 735 women 
are diagnosed with the cancer every year, and it is predicted that 1 in 150 women will 
develop the cancer by the age of 75. These numbers would be substantially lower if all 
women engaged in preventive behaviours. For instance, cytology tests are available to 
detect pre-cancerous lesions, and under Medicare, the standard Pap test is free to Australian 
women. It is estimated that through regular screening, 90 percent of cervical cancer cases 
can be prevented. Despite this fact however, there is evidence that Australian women are 
under-screened (Fernbach, 2001). Lack of awareness about cervical cancer and screening 
programs, and misunderstandings about the eligibility to these programs are among the 
leading reasons for this trend, suggesting that raising awareness is a necessary step towards 
successful cervical cancer prevention (Belkar et al. 2006; Mullins et al., 2008; Fernbach, 
2001).  
 
The most recent awareness campaign at a national level in Australia was launched in 2007. 
The campaign was led by a television advertisement aired through national networks 
prompting women to make a screening appointment if their last Pap test was more than two 
years ago. The graphics of the advertisement had a broad appeal (as opposed to a targeted 
campaign to a specific group) and did not feature a model woman’s age or ethnicity. The 
experiences of previous health-oriented campaigns in general suggest that televised 
messages are a powerful means of influencing the behaviour of their audiences (Mullins et 
al., 2008; Dobbinson et al., 2008; White et al., 2003).  
 
In April 2007, the Australian government also began a vaccination program. Australia is 
among the first countries worldwide to launch such a program at a national scale. Scientific 
research has led to the invention of a vaccine that could prevent 70 percent of cervical 
cancer cases. Unlike other forms of cancer, the cause of cervical cancer is known: infection 
by the Human Papilloma virus (HPV) (Franco et al., 1999). Immunity to HPV therefore 
avoids the pre-cancer stage all together. The vaccination program provides Gardasil, a HPV 
vaccine, free to females aged 12 – 26 years old as it is most effective when received prior 
to sexual debut. The public was informed about the availability of the vaccine through 
  
articles, banners, posters and pamphlets, but it was not aired through television, like the 
screening promotion campaign.  
 
The aim of this study is to examine women’s screening preferences in response to these 
interventions: the screening promotion and the vaccination program. The approach taken 
extends policy evaluation study to include analysis of the effects of the interventions on the 
screening determinants. Specifically, discrete choice experiments (DCEs), a form of stated 
preference (SP) technique, are used to elicit women’s screening preferences as well as their 
valuations of various screening factors. SP data have become increasingly popular in health 
economic studies, providing behavioural data which are not available from revealed 
preference (RP) data sources (e.g., market survey) (Fiebig et al., 2009; Salkeld et al., 2000; 
Lancsar et al., 2007; Scott and Vick, 1998; Hall et al., 2002; Ryan et al., 2006). By 
analysing the effects of the interventions on the screening determinants, in addition to their 
impact on choices, policymakers can make informed use of these factors to reshape 
screening behaviour in the future. The identification of the effects of the interventions will 
be achieved through comparisons of outcomes of the ‘treated’ and ‘control’ groups, in the 
standard sense that only the former was exposed to any intervention. The availability of an 
identical DCE conducted in 2004, before both interventions were introduced (DCE1), 
provides one control group. In addition, several other control groups are formed through 
spatial variations and randomisation in the follow-up DCE collected after both 
interventions (DCE2). These extra comparison groups are useful to isolate out any common 
(time) trend effect.  
 
The existing literature predicts that awareness would increase women’s willingness to be 
screeneed (Fernbach, 2001; Marcus and Crane, 1998; Jenkins et al., 1999; Mullins et al., 
2000). A previous screening promotion campaign in New South Wales, for instance, 
recorded a 30 percent increase in screening uptake within 4 months of the promotion 
campaign (Shelley et al., 1991). However, never before has a screening promotion 
campaign been joined with a vaccination program, another means to prevent cervical 
cancer. These two interventions may support one another, but the vaccination program may 
also counteract the screening campaign’s effectiveness, for example due to misconceptions 
that vaccination can substitute for screening (Newall et al. 2007; Kulasingam and Myers, 
2003). This study will provide the first results on these issues. 
  
Background 
Cervical cancer is a cancer of the cervix. The cancer develops when women are infected 
with high-risk strains of HPV (13-18 strains) for a number of years. Cigarette smoking, 
alcohol consumption, having multiple partners, and Human Immunodeficiency virus (HIV) 
infection are all associated with the development of the cancer.  
 
As the progression of the cancer to an invasive state is slow (up to 10 years) and pre-
invasive stages are largely asymptomatic, regular screening is crucial. Early detection of 
abnormal cells is known to have high curative rates. In Australia, the current 
recommendation states that women should begin screening between the age of 18 and 21, 
or a year after commencing sexual activity, whichever is later, and may stop at the age of 
70. The recommended interval between tests for asymptomatic women is 2 years. In 1988, 
the government set up a committee to manage all aspects of the cervical screening process, 
which is currently called the National Cervical Screening Program (NCSP). One of the 
features of the NCSP is a reminder system to maintain women’s participation in the 
screening program and follow-up of women with detected abnormalities.  
 
For the past 40 years, the Pap smear test has been the main means of cervical screening, but 
recently alternative tests have been produced. The liquid-based Pap test is more sensitive 
than the conventional (standard) Pap test, and is subjected to less preparation, reading  and 
interpretation errors (e.g., due to presence of obscuring objects), which commonly cause 
false-negative results in the standard Pap test. Another recent technology is a HPV test to 
detect specifically high-risk strains of HPV. When used in conjunction with a Pap test, this 
test is almost 100 percent accurate. Meanwhile, a Pap test alone is typically about 50-85 
percent accurate (Salmeron et al., 2003; Wright et al., 2000).   
 
Given the causal link of HPV infection to cervical cancer, scientists have also developed a 
HPV vaccine to target the initial HPV infection. Gardasil is a HPV vaccine that has been 
clinically proven almost 100 percent effective in preventing infections from HPV strains 16 
and 18, which together account for 70 percent of cervical cancer cases (and 90 percent of 
genital warts). Getting the vaccine does not exempt women from screening because it does 
  
not protect against other high-risk strains of HPV or eliminate existing exposure to HPV. 
The vaccine is therefore most effective when received prior to sexual debut.  
 
Demand for prevention 
The classical economic explanation for the demand for preventive measures can be traced 
back to Grossman’s (1972) human capital model of investment in health stock. In the 
model, high income earners and highly educated individuals are more likely to engage in 
preventive behaviour than their low-income and lowly educated counterparts because they 
expect larger life-time pay-offs from doing so; the return for good health is increasing in 
both education and income. On the other hand, older individuals have less incentive to 
participate in preventive behaviour because the pay-off period for their investment is 
shorter. Using US data, Kenkel (1994) finds support for the predictions of the model with 
regards to income and education. Likewise, Sabates and Fienstein (2006) highlight the role 
of education in screening uptake using data from the UK. They argue that education 
increases the likelihood of uptake of preventive measures because it is positively related to 
the mediating factors of participation, such as awareness, health knowledge and 
communication with health professionals. Using continuing education as a measure of new 
knowledge, they find that knowledge increases uptake of cervical screening. Meanwhile, 
older women are not less likely to screen compared to younger women (Rodvall et al., 
2005). 
 
Other determinants of screening uptake are environmental factors, especially knowledge. 
There has been evidence that the general public is ill-informed about cervical cancer (Klug 
et al., 2005; Marshall et al., 2007). Without awareness, women would not be able to make 
informed decisions. Marshall et al. (2007) conduct a survey involving some 2,000 adults to 
find that only 30 percent knew some factors related to cervical cancer, and just 2 percent 
correctly recognised ‘persistent HPV infection’ as its leading cause. Fylan (1998) finds that 
non-participation in screening can be explained by lack of awareness of screening benefits 
and misunderstanding of what information Pap test results provide. Many women wrongly 
believe that the purpose of screening is to review existing cancer stages, thereby 
discouraging those who consider themselves clear of the cancer from being screened. On 
the other hand, when the information barrier is lifted, experimental study has found that 
  
women who previously had limited knowledge of preventative care were participating in 
screening (Jenkins et al., 1999).  
 
Screening decisions are also influenced by preferences and motives. Fear of cancer for 
instance, has been found to be among the reasons why women avoid screening (Fylan, 
1998; Cullen et al., 2004; Skrabanek, 1985). On the other hand, motivation and beliefs 
about susceptibility of contracting the cancer (e.g., due to family history) tend to encourage 
participation in screening (Mullahy, 1999).  
 
In addition to these demand-side factors, screening participation may also be supply-driven 
or induced by government policies. For instance, in some countries, such as Australia and 
the UK, the government provides monetary incentives to health providers for screening a 
large number of eligible women. Myers et al. (2008), indeed argue that the bulk of the 
observed screening rate in the UK is due to opportunistic screening, in which the screening 
is initiated by the health providers.  
 
Discrete Choice Experiments 
A novelty of this study is the use of DCEs in a policy evaluation context. A DCE is one 
stated-preference (SP) method of producing behavioural data that asks its respondents 
(subjects) for their preferred choice, as opposed to observing their actual decisions in real 
market situations (which fits a type of revealed-preference (RP) data). The behavioural 
foundation of SP methods is Lancastrian consumer theory (Lancaster, 1966), which 
proposes a decomposition of utility derived from the consumption of a product into the 
utilities derived from its attributes. Hence, in a DCE, the product of interest is described by 
its attributes and their associated levels (possible cases of an attribute), which jointly set a 
scenario. Studies have found that although stated choices are made in a hypothetical 
setting, in which there is no real consequence of making the choice, one goes through a 
similar decision making process as in the real market setting (Louviere et al., 2000).    
 
The DCEs in this study contain the screening determinants and test options. The first DCE 
(DCE1) was developed by Fiebig et al. (2009) in 2004 (pre-interventions) to quantify the 
role of these screening factors in women’s screening decisions. The contents of the DCE 
were guided by extensive reviews of the literature on cervical screening decisions and pilot 
  
surveys. The study finds that both GP’s characteristics and recommendations are highly 
influential on women’s screening choices. Participation is more likely if the GP is female 
and/or is the regular GP seen by women for other health services. Women are also found to 
place a particularly high value on tests that have low false positive rates (indicating 
abnormality when there is no abnormality). In June 2007, after both government 
interventions were introduced, the experiment was rerun (DCE2). The remaining of this 
sub-section will describe the content of the DCEs in detail.  
 
A scenario is described by a combination of alternative-specific attributes, which reflect the 
characteristics of a given test, and common or context attributes, which supposedly capture 
the environment in which the screening decision has to be made. As the names suggest, 
common attributes are fixed across alternatives. There are 3 alternative-specific attributes 
according to whether the Pap tests are a standard Pap or a liquid-based Pap test. These are 
cost and accuracy, as measured by false positive (indicating abnormality when there is no 
abnormality present) and false negative (concluding no abnormality when abnormality is 
present) rates. Another set of alternative-specific attributes vary with the alternative to have 
the HPV test in addition to the Pap test. These attributes are cost and GP recommendation 
for the additional test. Except for recommendation, all alternative-specific attributes have 4 
levels, giving 2 x 4 x 4
3 x 2 distinct combinations between them. Meanwhile, common 
attributes include time since last test, GP characteristics, and the national guidelines on 
recommended screening intervals. All together, there are 6 context attributes with 4 levels 
and 2 levels, giving 4
3 x 2
3 (512) distinct combinations between them. Table 1 summarises 









Table 1: Attributes and levels in the DCE 
Attributes Levels 
Common   
Last cervical screening appointment  1 year ago; 2 years ago; 3 years ago; 5 years ago 
The recommended screening interval  1 year; 2 years; 3 years; 5 years 
Contact with GP   Regular GP seen for most care; Never seen before  
Sex of GP  Female; Male 
Recommendation of GP  No test; Standard Pap; Liquid-based Pap; Any Pap test 
Financial incentive to GP  No; Yes 
    
Alternative-specific (Pap test)  Standard Pap   Liquid-based Pap  
Cost of Pap test  $0; $10; $20; $30   A+$10; A+$20; A+$30; A+$40   
False negative rates   1/20; 1/15; 1/10; 1/5   1/100; 1/33; 1/20; 1/10 
False positive rates   1/1000; 1/250; 1/150; 1/100  1/2000; 1/500; 1/150; 1/100 
    
Alternative-specific (HPV test)   No HPV test  HPV test 
Cost of HPV test   0  $50; $100; $150; $200 
Recommendation to additional test  0  No test; test 
 




3 x 2) possible scenarios. This product is very large and administering all 
of them to a respondent is both impractical and would not be manageable by the 
respondents. In addition, some scenarios are ‘dominated’, in the sense that no rational 
individual would choose to be tested when faced with these scenarios, for example, the 
scenario in which the highest cost of a test appears together with the worst accuracy levels. 
Experimental design techniques are therefore applied to reduce the potential scenarios to a 
manageable fraction, while retaining the ability to identify the utility weight of each 
attribute independently of each other. Specifically, the survey design construction follows 
the D-optimality criterion for main effects only design described in Burgess and Street 
(2004a, 2004b). For a given number of attributes and levels included in the experiment, and 
for a given number of alternatives in a choice set, an optimal (or near-optimal) design is an 
efficient one, with the smallest (or with negligible difference from the smallest) variance of 
the parameters to be estimated. The virtue of statistical efficiency for the estimations of the 
utility weights later on is its precision, which is difficult to control with RP data.  
 
Nonetheless, the optimal design theory is made under the assumption that the experiment 
contains only alternative-specific attributes, as stated-choice experiments generally have 
this feature. To incorporate common attributes, Fiebig et al. (2009) therefore propose 
considering the design problem as a two stage problem. In the first stage, the choice 
  
problem is the decision to undertake screening, given the common attributes, and in the 
second stage, the choice problem is deciding which type of test to take.  
 
The process leads to 512 scenarios, comprising 32 treatment combinations for the common 
attributes and 16 treatment combinations for the alternative-specific attributes. The 
scenarios are then blocked into 16 versions of 32, with each version including all 32 
treatment combinations for the common attributes. A respondent is randomly allocated to 
one of these 16 versions. After considering a scenario, the respondents have to choose 
whether to have a standard Pap test (P) or a liquid-based Pap test (L), and whether to have 
an additional HPV test with the selected Pap test (PH, LH). The No test (NT) option is also 
available, making the alternatives exhaustive (i.e., a ‘forced choice’ experiment). An 
example of a scenario is given in Appendix A. 
 
The surveys also collect personal information on the respondents, such as age and income. 
Also included in DCE2 are four additional questions regarding their awareness about the 
HPV vaccine and test and personal experience with any of these measures.  
 
Methodology  
The econometric model 
Given its foundation in utility theory, the decision-making process in a DCE by a utility-
maximising respondent is assumed to involve a comparison of indirect utility functions. 
The alternative chosen is the one attaining the highest level of utility. Thus, if 
(1)  isj isj isj V U ε + = , 
where    represents the indirect utility function of respondent i in scenario   for 
alternative j ,   being the deterministic component of the utility and 
isj U s
isj V isj ε  capturing all 
other factors affecting utility that are not included in V  (e.g., excluded attributes or 
unobserved consumer taste), then the respondent   will choose j over l if:  i
(2)   isl isl isj isj V V ε ε + > + ,     j l ≠ ∀    (l, = j P, L, PH, LH, NT). 
The presence of the random component ε  in (2) makes it a probabilistic statement. The 
probability that the alternative j is chosen over the other possible alternatives therefore can 
be written as: 
  
(3)  ) Pr( j l V V isj isl isl isj ≠ ∀ − > − ε ε . 
 
For the deterministic component, let 
(4)  δ β
' ' ~ ~
i isj isj z x V + = , 
where β
~  and δ  are vectors of parameters to be estimated, measuring the utility weights of 
attributes  isj x ~  on screening choice and the influence of socio-demographics   on choice, 
respectively. The different levels of screening attributes are effects-coded, whilst the 
different categories of socio-demographic variables are represented by a set of dummy 
variables. Effects-coding the attributes separates out their effects from the effects of the 
omitted categories of the socio-demographic variables on screening choice. For each 
attribute, the parameter for the reference group is internalised in the parameters of the 
included levels, and is given by the negative of their sum (see Bech and Gyrd-Hansen, 
2005 for further arguments for effects-coding). 
i z
 
By assuming a probability distribution for ) ( isj isl ε ε − , we can estimate the deterministic 
component of the utility. The multinomial logit (MNL) model that has been the industry-
standard for multiple-alternatives problems arises if we assume iid (identical and 
independently distributed) extreme value Type I distribution. MNL however is 
inappropriate in this case given that each respondent provided responses to several 
scenarios, so serial correlation across scenarios, instead of independence, is more likely. 
Furthermore, substitution patterns between the test alternatives are unlikely to be consistent 
with the independence of irrelevant alternative (IIA) assumption of MNL, which requires 
proportionate substitution across all pairs of alternatives. Thus, a more flexible mixed logit 
model (MXL) will be used. McFadden and Train (2000) have shown that MXL has the 
capability of approximating any random utility model.  
 
Let us rewrite (4) so as to separate out the alternative-specific constants (ASCs) from  isj x ~  
and denote the remaining vector of attributes as  . The model is now:  isj x
(5)   ,  δ β α α α α α
' '
i isj iNT isj iLH isj iPH isj iL isj iP isj isj z x dNT dLH dPH dL dP V + + + + + + =
where dP, dL, dPH, dLH and dNT are dummy variables for standard Pap, liquid-based Pap, 
joint standard Pap and HPV test, joint liquid-based Pap and HPV test, and no test option, 
  
respectively. The modification from (4) also allows for a random intercept  ij α . Further, 
assume that 
(6)   ij j ij ω α α + = ,   ~ ij ω ) , 0 ( Ω iid , 
where  j α  represents its mean and  ij ω  denotes a random component that represents a 
deviation from the mean. A significant deviation around the mean would indicate the 
presence of inherent (individual-specific) taste heterogeneity in the sample population.  ij ω  
would appear as a separate error component with  isj ε , resulting in a composite error term 
ij isj v isj ω ε + = .   thus consists of two parts, isj v isj ε  that is iid and  ij ω  that would follow a yet-
to-be specified distribution and induce heteroskedasticity and correlation over alternatives. 
Notice that  ij ω  varies over respondents, but is fixed over repeated scenarios faced by a 
respondent, thereby inducing serial correlation across scenarios. This implies that even if 
 is specified as diagonal,   would still be correlated over alternatives. This way of 
introducing non iid errors is often called ‘error component’ specification. 
Ω isj v
 
The normal distribution is used for (6). This assumption is arbitrary, but when there is no 
strong a priori expectation with regard to the sign of the random intercepts and the length 
of the tail(s) of the true taste distribution, normality is plausible. The normal distribution 
has support on each side of zero, reflecting that there are people who tend to choose a given 
alternative, and there are others who tend not to prefer it. The location of the mean will 
suggest the prevalence of each kind of preferences. On the other hand, in circumstances 
where the random coefficient is specified for a variable that has a strict domain say, of only 
non-negative values such as cost, the normal distribution may not be appropriate.  
 
Under the normality assumption, the choice probability in the MXL model is a mixture of 
logits with a multivariate normal mixing distribution. Conditional on the random 
parameters, the probability will follow the standard logit specification. However, as 
respondent’s taste is unobserved, the unconditional probability is an integral of the 
conditional probabilities over all possible values of the random parameters, weighted by its 
probability density function. This problem has no closed-form solution and is approximated 
numerically through simulation. For respondent   facing a scenario   having a specific  i s β  
  
and δ , values for  ij α  are drawn from its distribution, and using these draws, the probability 
that the alternative  j  is chosen is given by:  














il l i isl
r









ω α δ β
ω α δ β  
where j, l = P, L, PH, LH. As only differences in utilities matter, the no test alternative is 
chosen as the base with an associated utility of zero. The probability that the reference case, 
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The mean of these simulated probabilities is then taken to the objective function to be 
maximised by Maximum Likelihood. For sufficiently large draws (R), the simulated choice 
probabilities have been shown to be consistent estimates of the unconditional choice 
probabilities. Halton draws are used in the simulation instead of random draws to increase 
the accuracy of estimation. The random intercepts are allowed to be freely correlated with 
each other; implying that   in (6) is given by:  Ω
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Treated and control groups  
To identify the effects of the interventions on screening choice and utility weights, we need 
definitions of the treated group, which has been affected by the interventions, and the 
control group. The DCE1 respondents are a clear control group, as this survey was 
collected pre-interventions. However, relying on time variation has the limitation of not 
knowing the extent of each woman’s exposure to the interventions; there is no information 
in the survey, for example, about women’s awareness of the screening promotion 
advertisement. In the extreme case, all women in DCE2 are unaware of both the screening 
promotion materials and the vaccination program, making them fit the definition of a 
control group. To deal with this problem, several other definitions for the treated and 
control groups are proposed. There are 4 cases in total, which care summarised in Table 2.  
  
 
Table 2: Comparison samples 
Case Treated  Control 
1.  DCE2   DCE1  
2.  DCE2 with prior knowledge (Prior)  DCE2 without prior knowledge (No prior) 
3. 
 
DCE2 without prior knowledge, informed  
(Informed) 




DCE2 with prior knowledge, informed  




Essentially the other comparison samples (Cases 2–4) are split-samples of DCE2. Case 2 
uses the extra questions about HPV awareness and define respondents who have ever heard 
of, or experienced the HPV test or vaccine prior to the experiment as treated. Meanwhile, 
Case 3 and 4 make use of the randomisation exercise in DCE2, which allocated respondents 
into two groups, but only one of the two groups was treated. The treatment was information 
on HPV facts and HPV-based measures (Appendix A). Outside an experimental setting, it 
is very difficult to have control over each woman’s exposure to relevant information, as she 
can obtain information from various sources and at various levels. In an experimental 
setting, on the other hand, both the level and the content of information known to subjects 
are fully controlled by the experimenter. To ensure that women in the treated group have 
just the amount of information set by the experiment, those with prior knowledge of HPV 
are excluded. Finally, women who have prior knowledge of HPV and got randomly 
allocated into the treatment group can also form a treated sample.  
 
The MXL model is estimated independently for treated and control samples. By doing so, 
we can test if samples have different scales (the overall extent of unobserved 
heterogeneity). In discrete choice models, the scale factor is confounded by the utility 
parameters. However, the identification of the scale factor is desirable, as a larger scale 
implies a lower variance of the unobservables, which may result from increased awareness. 
Furthermore, from a policy point of view, different policy strategies are appropriate if 
women have the same response patterns with respect to choice attributes, but one group of 
women is more variable in its behaviour than others, from those that are appropriate in the 





Screening choice responses 
The respondents are based on random samples within New South Wales. Each experiment 
involves a different sample. DCE1 consists of 167 previously-screened women. As each 
respondent provided responses to 32 scenarios, there are 5,344 respondent-scenarios. In 
DCE2, there are 154 previously-screened women to make a total of 4,928 respondent-
scenarios. However, 25 respondent-scenarios have to be dropped due to multiple responses 
in a given scenario. Compared to women in DCE1, women in DCE2 tend to be younger, 
more educated and have higher incomes (Appendix B1). DCE2 also consists of more 
foreign-born women than DCE1. Accounting for this difference in country of birth is 
important, as it is a good predictor of ethnicity, which has been found to be influential for 
screening behaviour. For instance, Belkar et al. (2006) find that Asian women in Australia 
are less familiar with cervical screening, and therefore are less likely to be tested.  
 
Before proceeding further, it is worth mentioning the presence of 4 non-traders in DCE2 
(none in DCE1): one woman always chose no test, another always chose a standard Pap, 
and the rest always chose a joint standard Pap and HPV test. Non-trading behaviour is 
consistent with lexicographic preferences, whereby an individual’s choice is based solely 
on the levels of a sub-set of attributes, ignoring all other differences. This kind of 
preference does not have a continuous utility function representation, which was assumed 
in (1) (see Campbell et al., 2006 for explicit modelling of lexicographic orderings). A 
decision therefore has to be made as to whether to exclude them from the analysis. It was 
decided that only one of them should be dropped, because she is over 70 years of age and 
cervical screening is no longer recommended for women in this age group. The other non-
traders are retained because they can be accommodated by MXL.  
 
The distribution of responses is reported in Table 3. In all cases, the shares of women who 
chose no test are shown to be higher in the treated than in the control samples. This pattern 
is inconsistent with the prior expectation that awareness would motivate screening 
participation. Investigating further, this overall increase in non participation is found to be 
driven by young women’s choices (Appendix B2). In comparison, there is no distinct 
pattern across income groups. This age-specific phenomenon thus hints that the drop in 
  
participation rate is related to the parallel vaccination program, which is targeted to these 
young women. For instance, they may falsely believe that vaccination and screening are 
alternative strategies to prevent cervical cancer, and that getting vaccinated can substitute 
for screening. If so, the vaccination program actually counteracts some of the effect of the 
screening promotion campaign, rather than working together with it to achieve the common 
goal of cervical cancer prevention. Another factor that could lower screening participation 
is the reduced value of screening programs to women as the HPV vaccine eliminates HPV 
strains that are readily detected by Pap tests (Schiffman, 2007). Meanwhile, the share of a 
given test alternative is on average stable between a pair of comparison samples.   
  
Table 3: Sample mean of choice responses  
Case No.  1  2  3  4 
Choice/Sample  Treated Control Treated Control Treated  Control  Treated  Control 




No test  0.429  0.373  0.431  0.419  0.432  0.410  0.444  0.373 
Standard 0.228  0.296  0.188  0.271  0.243  0.292  0.197  0.296 
Standard, HPV test  0.103  0.095  0.099  0.108  0.106  0.110  0.068  0.095 
Liquid 0.118  0.118  0.126  0.111  0.148  0.083  0.126  0.118 
Liquid, HPV test  0.123  0.119  0.157  0.090  0.073  0.105  0.165  0.119 
 
Preference and attribute values 
The MXL models are estimated using the routine by Hole (2007) in STATA. Table 4 
reports the results for Case 1. First considering the random intercepts, in the treated sample 
(DCE2), all the mean intercepts are negative and statistically significant, predicting that in 
given a scenario, the reference women in the sample (i.e., young women with low 
education and income, born in Australia, and who were never smokers) would tend to 
choose not to be tested. On the other hand, the reference women in the control sample 
(DCE1) may choose to have a standard Pap test. The location of each of the mean 
intercepts in DCE2 is further to the left from its counterpart in DCE1, suggesting results 
that are consistent with the raw data discussed earlier, that the joint interventions have 
generated negative preferences towards testing in general.
1 However, the interventions 
                                                 
1 One can find the probability of getting a value less than 0 of a normally distributed random variable with 
mean and standard deviation equal to the MXL estimates for each alternative. For instance, for a standard 
  
 
                                                                                                                                                
seem to reduce the extent of heterogeneity surrounding a given test alternative. The 
standard deviations around the means are all large and significant, but are slightly smaller 
in magnitude in DCE2. Moreover, these deviations are not always larger than their 
respective means, which is the case in DCE1. Meanwhile, both samples exhibit significant 
correlation in pairwise alternatives, except between P and LH. This exception is sensible, 
as serial correlation is personal, and women who have a taste for technology would be most 






Pap test the probability of getting a value less than 0 of a normally distributed random variable with mean 
1.5 and standard deviation 2.5 is 0.73 in DCE2.   
Table 4: MXL results – Case 1 
   DCE1  DCE2     DCE1  DCE2 
    Coeff. p  Coeff. p    Coeff.  p  Coeff. p 
Socio-demo        Alt-spec: Pap test    
Age  0.005  0.620  0.004  0.693  Cost: A+$20    0.318  0.000  0.268  0.000 
Trade certificates  -0.222  0.618  0.312  0.478  Cost: A+$30    0.060  0.189  0.036  0.444 
Some uni  -0.525  0.173  0.889  0.139  Cost: A+$40   -0.418  0.000  -0.449  0.000 
Completed uni  0.160  0.658  0.139  0.755  Cost: A+$10   0.041    0.146   
Inc $50- $80,000  0.342  0.343  -0.594  0.183  FP: 1/250, 1/500   0.021  0.652  0.113  0.015 
Inc >$80,000  0.243  0.511  0.085  0.850  FP: 1/150, 1/150   -0.029  0.524  -0.059  0.208 
Inc missing  -0.972  0.036  0.671  0.586  FP: 1/100, 1/100  -0.205  0.000  -0.321  0.000 
Not Australian-born  0.075  0.853  0.284  0.425  FP: 1/1000, 1/2000  0.214    0.268   
Current smoker  -0.452  0.182  0.598  0.164  FN: 1/15, 1/33   0.024  0.590  0.041  0.379 
Ex-smoker  -0.114 0.762  1.094 0.017 FN:  1/10,  1/20    0.028 0.533  0.055 0.239 
Common         FN:  1/5,  1/10  -0.239 0.000  -0.296 0.000 
Interval: 1 year  0.715  0.000  0.811  0.000  FN: 1/20, 1/100    0.186    0.201   
Interval:  3  years  -0.127 0.062 -0.137 0.061 Alt-spec: HPV test        
Interval: 5 years  -0.858  0.000  -1.021  0.000  Rec: HPV test   0.571  0.000  0.517  0.000 
Interval: 2 years  0.270    0.347    Rec: no HPV test  -0.571    -0.517   
Last screen: 2 years   -0.061  0.374  -0.205  0.004  HPV cost: $100  -0.028  0.719  0.005  0.955 
Last screen: 3 years   0.295  0.000  0.406  0.000  HPV cost: $150  -0.411  0.000  -0.540  0.000 
Last screen: 5 years   0.951  0.000  1.102  0.000  HPV cost: $200  -0.784  0.000  -0.694  0.000 
Last screen: 1 year   -1.185    -1.303    HPV cost: $50  1.223    1.229   
GP:  new  -0.522 0.000 -0.605 0.000 Intercepts (ASCs)        
GP: seen before  0.522    0.605    P  -0.445 0.414  -1.500 0.007 
GP:  male  -0.469 0.000 -0.705 0.000 Std.  dev  2.671 0.000  2.489 0.000 
GP:  female  0.469   0.705   L  -1.331 0.014  -2.307 0.000 
Rec:  standard  0.540 0.000  0.492 0.000 Std.  dev  2.481 0.000  2.236 0.000 
Rec: liquid   0.067  0.318  0.182  0.010  PH  -2.299 0.000  -2.898 0.000 
Rec: any Pap  0.365  0.000  0.337  0.000  Std. dev  2.943  0.000  2.786  0.000 
Rec: no test  -0.972    -1.013    LH  -2.541 0.000  -3.127 0.000 
GP: get finc incentive  -0.049  0.215  0.059  0.153  Std. dev  3.975  0.000  2.940  0.000 
GP: no finc incentive  0.049    -0.059    Correlation*       
        P, L  0.498 0.000  0.657 0.000 
        P, PH  0.507 0.000  0.504 0.000 
         P, LH  0.057 0.115  -0.012 0.844 
         L, PH  0.558 0.000  0.387 0.000 
         L, LH  0.765 0.000  0.449 0.000 
        PH, LH  0.675 0.000  0.715 0.000 
               
        N  26,720   24,355  
          Log L  -5,158     -4,681    
Note: Reported under Coeff column are MXL coefficients, and under p column is the probability value 
that the respective coefficient is equal to zero. Coefficients without probability values are coefficients of 
the reference group. ‘Rec’ stands for GP’s recommendation. For standard Pap, the cost levels are $0, 
$10, $20 and $30, and the costs of liquid-based test add to these cost. For false positive (FP) and false 
negative (FN) rates, the first figure is for standard Pap and the second is for liquid-based test. * p-values 
of the covariance terms. The number of draws for the simulated probabilities is R = 2,000. 
  
Next, to compare attribute parameters from the two samples, Figure 1A plots the set of 
estimates from DCE2 against those obtained from DCE1. In non-linear models, this device 
isolates differences in scales (overall variance) from genuine differences in utility weights; 
estimates from different samples are not directly comparable due to confounded scales, 
which can be sample-specific. Scaling phenomenon implies a systematic difference 
between the parameter estimates from different samples, with estimates from the sample 
exhibiting a larger scale being scaled down. On a scatter plot of treated sample against 
control sample, these estimates will have a linear relationship with slope steeper than a 45-
degrees line. Meanwhile, points above the45-degree line indicate larger estimates in the 
treated sample.   
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For the attributes, the plot shows that the differences in utility weights are largely 
systematic. While there is no obvious reason why women should change their valuations of 
screening attributes following the interventions, one can imagine that awareness of 
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screening importance reduces the weights on costs and/or increases the weights on 
accuracy. The results however suggest that screening participation has always been highly 
influenced by provider characteristics and recommendation, and costs and test accuracy 
received unchanging weights. Further, the statistical significances of most attribute weights 
are comparable in the two samples, except for the effect of time since last test. In DCE2, 
the reference women who are on time for screening according to the national guideline 
(i.e., those who had their last test within 2 years) are significantly less likely to participate 
in screening. The corresponding coefficient is also negative in DCE1, but is not statistically 
significant. This result replicates the declining trend in screening participation during the 
survey gap.  
 
The different coding system for attributes and the socio-demographic variables turns out to 
be important, as the effects of socio-demographics, unlike the attributes’ weights, vary with 
samples. Although most of them are not statistically significant, the reversing sign of the 
coefficients on education and smoking variables to positive is noteworthy. That is, in 
DCE2, higher education increases the propensity to test, and smokers and ex-smokers are 
more likely to test than non-smokers. The changing behaviour related to smoking habits in 
particular is a positive outcome from the perspective of women’s health, as smoking 
increases the risk of developing cervical cancer. The coefficient on ex-smokers is 
statistically significant at the 5 percent level.  
 
Figure 1B-D summarises the results from other cases. The underlying results are reported 
in Appendix C1-3. As in Case 1, the relationship between attributes’ weights in the other 
comparison samples is largely one-to-one. On the other hand, inherent taste for screening 
and socio-demographics’ effects are sample-specific; due to the dummy-coding of the 
socio-demographic variables, they are linked with the random intercepts.  
 
Comparing the inherent preference for screening between women with prior knowledge of 
HPV (Prior sample) and those who were unaware of it (No Prior sample), the reference 
women in the Prior sample are found to be much less averse towards screening (Appendix 
C1). In Figure 1B, this result is depicted by all the mean intercepts of the tests (ASCs) 
located above the 45-degrees line. However among women in the No Prior sample, those 
who have smoking history and/or have high income and education are much more likely to 
22 
  
participate in screening. Meanwhile, from the comparison samples based on randomisation, 
women in the Informed sample tend to be more averse towards testing than those in the 
Uninformed sample (Appendix C2). In Figure 1C, in contrast to the earlier result, all the 
test intercepts lie below the 45-degrees line. A similar pattern is portrayed in Figure 1D, in 
comparing women in DCE1 and women in the Prior, Informed sample. These last two 
results are somewhat puzzling given that the treatment in the randomisation exercise was 
information on HPV facts. A possible explanation has to do with women’s changing 
assessment of their susceptibility to developing the cancer. For instance, the treatment 
mentioned the causal link of HPV infection to cervical cancer and the fact that in most 
cases, the HPV infection will clear by itself. Women who had ever heard of HPV 
previously thought of cervical cancer as being caused by some other factors, which might 
have been more acute. If so, this new information may cause them to revise their risk of 
contracting the cancer downwards. Some women might have encountered the HPV test or 
vaccine, but even test participants could be unaware of HPV facts (Klug et al., 2005).  
    
Eligibility for free Gardasil 
Whether it is the parallel vaccination program in particular that creates the aversion 
towards testing can be checked by removing young women (under 30 years old), who are 
eligible for the vaccination program, from the DCE2 sample. This restriction reduces the 
sample by nearly half. Re-estimating the model, the results now find that all test means are 
statistically indifferent from zero, suggesting that the parallel vaccination program is a part 
of the story (Appendix C4). Meanwhile the results regarding the screening attributes are 
largely consistent with those obtained from the unrestricted sample; the correlation 
coefficient between them is 0.98. As additional information on the test preference of older 
women, the restriction was also imposed on DCE1, and it was found that all test mean 
intercepts are negative and significant. Variations around the means are substantial in any 
case, but that for the joint liquid-based Pap and HPV test alternative is considerably smaller 
in size in the DCE2 sample.  
 
To sum up, despite the screening promotion effort, the majority of women (still) prefer not 
to be screened. Spatial comparisons suggest that this is due to a reduction in the taste for 
screening related to HPV events. Meanwhile, the values of screening attributes to a typical 
woman and the overall scale, which one may interpret as measuring the extent of 
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uncertainty surrounding screening decision-making in general, appear to be independent of 
any intervention. The policy implication following these results is therefore for future 
screening promotion effort to integrate the HPV innovations. In particular, the relationship 
between cervical cancer, screening, HPV facts, and HPV-based measures must be 
communicated in an orderly fashion to avoid confusion and prevent women from making 
false self-assessments of their risk of developing the cancer. Better delivery of information 
may also reduce the uncertainties surrounding the screening decision.  
  
Policy simulations 
Given the significant role of providers in women’s screening decisions, stimulating their 
involvements seems to be a plausible strategy to boost screening rates. Using the attributes 
related to the GP in the experiment, simulation is used to forecast the impact of this 
strategy. As alternative strategies, let us consider a price reduction, which is the common 
policy instrument to increase demand and an investment in Research and Development 
(R&D) that produces a more accurate Pap test. Currently, the standard Pap test is covered 
by Medicare, but the newer tests would involve positive out-of-pocket costs. Meanwhile, 
with regards to test accuracy, the standard Pap test has a 1 percent false positive rate and a 
20 percent false negative rate. 
 
Consider the case for a representative woman who is on-time for screening (the last test 
occurred within 2 years). To reflect reality, attributes with real-life counterparts are 
specified accordingly; that is, 2 years recommended screening interval and accuracy levels 
as specified above. Other attributes are selected so that the predicted screening rate in 
DCE1 for 20-69 years olds is consistent with the actual two-year participation rate for these 
groups of women according to the Australian Institute of Health and Welfare’s (AIHW) 
report, which is 58 percent in 2003-2004 (AIHW, 2008). The corresponding market share 
for 2007 onwards is not (yet) available. This alignment requires the GP to be specified as 
male and as the regular GP of the women. The HPV test costs $50, and is not 
recommended.  
 
The ‘price effect’ ( ), ‘provider effect’ ( ) and ‘R&D effect’ ( ) to screening 
participation are found as follows: 
1 E 2 E 3 E
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where   is the sample size, and  N iNT P  is the individual average of the probability of no test 
(NT) alternative from 100 draws, drawn from their estimated distributions. The parameters 
are given by the MXL estimates. The superscript H  (L) denotes the case in which 
screening was recommended without the test type specified and the liquid-based Pap test 
costs an additional $40 ($10), superscript P ( ) denotes the case in which the GP 
recommended the standard Pap test (not recommending testing), and superscript   denotes 
the case in which the accuracy of the standard Pap increases to a 0.1 percent false positive 
rate and a 5 percent false negative rate. The R&D effect is found using the probability of no 




NT P , as the reference point. Within-sample variations are 
achieved by the random draws as well as variations in socio-demographics characteristics.  
 
Table 5 reports the results for (9) – (11). For the extent of the policy change considered, all 
of the three policies have considerable effects on the screening rate. The price subsidisation 
can reduce the non-participation rate by around 20 percent in most samples. Meanwhile, by 
encouraging health providers to take a more active role in screening promotion (perhaps, in 
women’s visits for other purposes), the non-participation rate can be reduced by 40 to 50 
percent. A large provider effect is indeed not impractical (Myers et al., 2008). R&D 
spending on technology research has a similar-size effect to the provider effect, but 
arguably, the R&D returns take longer. For an immediate impact, the government therefore 
may consider the price strategy, although a generous subsidy (in the above case 75 percent 
of the costs) may be needed for large effects, and/or extending incentives for opportunistic 
screening (e.g., amending the current Practice Improvement Program (PIP)). For the longer 




Table 5: Simulation results on the probability of no test 
Sample  N  1 E   Std. Dev  2 E   Std. Dev  3 E   Std. Dev 
      [%]  [%]  [%]  
DCE1   167  -0.051  0.006  -0.176  0.062  -0.079  0.011 
      [17.41%]    [43.92%]    [32.60%]   
DCE2  153  -0.076  0.007  -0.196  0.014  -0.118  0.016 
       [19.63%]  [40.24%]  [38.09%]  
95% CI of DCE1 means  (-0.067, -0.037)  (-0.222, -0.135)  (-0.112, -0.054) 
DCE2 Sub-samples             
No Prior  77  -0.097  0.014  -0.197  0.023  -0.127  0.030 
      [23.03%]    [38.80%]    [39.36%]   
Prior  76  -0.068  0.009  -0.223  0.025  -0.126  0.026 
      [17.29%]    [43.15%]    [39.06%]   
Uninformed  44  -0.074  0.019  -0.170  0.039  -0.106  0.033 
      [16.65%]    [31.69%]    [28.62%]   
Informed  33  -0.132  0.034  -0.242  0.054  -0.157  0.062 
      [31.87%]    [47.95%]    [55.42%]   
Prior, Informed  43  -0.074  0.017  -0.181  0.038  -0.100  0.033 
      [18.09%]   [36.92%]  [29.86%]  
95% CI of No prior means  (-0.012, -0.055)  (-0.234, -0.122)  (-0.173, -0.055) 
95% CI of Prior means  (-0.085, -0.035)  (-0.276, -0.129)  (-0.178, -0.053) 
Note: 95% CI denotes 95% confidence interval:
x x σ 2 ± . 
 
It is also of interest to predict the type of test women are most likely to take, had they 
participated in screening. Consider the ratio  



























1 ,     LH L PH P l , , , = ,  
which is used to indicate how women substitute away from non-participation to a test 
alternative following policies targeted to providers. The distributional behaviour for the 
other strategies will be similar, as within-sample sources of variations are not changing 
with strategies. (12) is a meaningful quantity in MXL, due to its flexibility in allowing for 
taste heterogeneity and choice dependence. In contrast, the measure would not vary over 
alternatives in the conditional logit model, which assumes proportional substitution.  
 
Figure 2 plots the distribution of  2 R  for women in DCE1 and DCE2 samples. It is shown 
that about half of the increase in screening participation is reflected in the take-up of a 
standard Pap test in DCE1, whilst in DCE2 larger shares are translated to the take-up of a 
HPV test. This exercise is repeated for women in the Prior and No Prior samples, and the 
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results are plotted in Figure 3. Women in the Prior sample are shown to be more likely to 
book for the advanced tests when participating, whilst women in the No Prior sample 
behave much more like women in DCE1, choosing the standard Pap test when 
participating. As HPV materials get recognised over time, this finding predicts a 
progressive departure from the conventional Pap test. As such, how to deal with the 
availability of the advanced tests should also be on the agenda of the policymakers. 
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Note: each quadrant plots the kernel density (%) of a given test alternative assuming Gaussian weights. 
The horizontal axis is 
2 R  for a given test. The dash (solid) line corresponds to DCE1 (DCE2) sample.  
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Note: each quadrant plots the kernel density (%) of a given test alternative assuming Gaussian weights. 
The horizontal axis is 
2 R  for a given test. The dash (solid) line corresponds to No Prior (Prior) sample. 
 
odel assumptions 
veral important technical points must be mentioned. The first one is 







the assumption of an additive, linear utility function. Generally, the linear-in-parameters 
specification is assumed by discrete choice models. To increase flexibility, attributes with 
multiple levels have been represented by categorical variables that allow for non-linear 
relationships between them and utility.  
 
The 
convenient way to accommodate non iid errors, it assumes that the main of source 
heterogeneity is inherent taste heterogeneity among women. Some variations however 
be related to a particular attribute, and the error component model does not capture this 
source of heterogeneities. Extending the model to also allow for heterogeneous preferenc
may improve the fit and explanatory power of the model, but the size of the resulting model 
can be overwhelming, as there are quite a number of attributes to be considered as random. 
The main source of heterogeneity could also be scale heterogeneity, instead of inherent 
taste heterogeneity, or a combination of inherent taste and scale heterogeneity, in which
case MXL may be inappropriate due to incorrect mixing assumptions. The application of a
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more flexible model, such as the generalized multinomial logit model (GMNL) proposed 
by Fiebig et al. (2009) to allow for alternative sources of heterogeneities is left for future 
study. The persistent results that attribute parameters between comparison sample pairs are 
almost perfectly related however suggests that the role of scale heterogeneity (in addition to 
the correlated taste heterogeneity) in the conclusions about the effect of interventions is 
minor.   
 
The third issue is also related to the adequacy of MXL. A way to measure the gain from 
estimating MXL from iid-based models is to compare their log-likelihood values. It is 
found that the improvements are quite substantial, measuring to 28 to 30 percent (22 to 28 
percent) of the log-likelihood values of the conditional logit model without (with) 
alternative-specific constants across samples and 14 to 26 percent of the log-likelihood 
values of MNL. Meanwhile, in terms of predictive power, MXL produces 46 to 50 percent 
overall correct prediction rates, in the sense of aligning predicted and actual choices. The 
predicted choice is given by the alternative with the highest probability of being chosen. 
For the random intercepts, 100 draws are used to compute the average individual 
probabilities, just like in the policy simulation exercise (Section 3.6.4). Table 6 reports the 
number of correct predictions for each test alternative and its actual cases. It is shown that 
the models generally lack power in predicting the “middle” test alternatives, liquid-based 
Pap (L) and joint Pap and HPV tests (PH), and perform better at predicting no test (NT) and 
Pap test only (P) alternatives. This pattern can be explained by the domination of the latter 
two alternatives as well in the actual cases. The Prior sample seems to be an exception, as 
the number of women choosing the variant test alternatives are more spread out in this 
sample, but the model was able to pick up the greater preference for joint liquid-based Pap 
and HPV test (LH) among these women. It is noteworthy however that if differences in 
probabilities between the test alternatives are small, the correct prediction rate provides 
limited information.        
 
Overall, the MXL specification selected appears to be a sensible one to use in this analysis. 
The key issue in identifying the intervention effect is the need to split the (DCE2) sample, 
making it infeasible to contemplate more flexible (complicated) models. 
 
Table 6: Correct prediction table 
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Sample     NT   P   PH   L   LH   Total 
DCE1 Correct  1,551  852  0  0  66  2,469 
  Actual 1,991  1,582  506 631 634  5,344 
DCE2  Correct  1,714  491  18 3 64  2,290 
  Actual 2,070  1,118  504 578 601  4,871 
No  Prior  Correct  843  302  18 1 32  1,196 
  Actual 1,025  662 265 272 220  2,444 
Prior Correct  901  112  8  35  108  1,164 
  Actual 1,045  456 239 306 381  2,427 
Uninformed  Correct  438  247  4 0 6  695 
  Actual  570 406 153 116 146  1,391 
Informed Correct  389  132  9 1 0  531 
  Actual  455 256 112 156  74 1,053 
Prior,  Informed  Correct  539  80 0 15  54  688 
    Actual 610  271 93 173  226  1,373 
 
Conclusion 
This study has analysed changes in women’s attitudes towards cervical screening following 
the latest (2007) screening promotion campaign and a parallel vaccination program 
providing HPV vaccine, Gardasil, in Australia. Discrete choice experiments were used to 
elicit women’s valuations of screening attributes and their preferences for a test alternative. 
The successes of previous screening promotion campaigns and other preventive health 
campaigns (e.g., the SunSmart program) led to the expectation that the promotion 
campaign would substantially increase the cervical screening rate. However, it is found that 
the proportion of women willing to be screened is generally lower after the joint 
interventions. This trend is unexpected, but at least in Australia, there is no precedent for 
concurrently running a screening promotion campaign and a vaccination program. 
  
The reduction in the participation rate appears to be associated with HPV events. First, the 
reduction in willingness-to-screen is particularly marked among young women, who can 
obtain Gardasil for free under the vaccination program. Meanwhile, there is little evidence 
that given individual characteristics, the older women are averse towards testing. These 
results therefore suggest that while screening and vaccination are both preventive means for 
cervical cancer, the effectiveness of the screening promotion effort need not be enhanced 
by the vaccination program. Second, women who were newly informed about HPV facts 
30 
  
tend to have a stronger aversion towards test alternatives than otherwise similar uninformed 
women. Presumably, their willingness to be screened fell as they misinterpreted HPV facts 
and re-adjusted their risk of developing the cancer downwards. If so, it is clear that women 
require clarification about the position of screening in the face of the innovations related to 
HPV.  
 
Through a simulation exercise, several potential strategies to increase future screening rates 
were evaluated, and the result suggests that encouraging a more active role of health 
providers is the most effective strategy among those considered to achieve this goal, 
capable of reducing the non-participation rate by close to one half. Meanwhile, R&D 
spending on technology that improves test accuracy can be justified on the basis of its 
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Appendix A: Example of a scenario  
Scenario 1:  
You are visiting the GP who gives you some information about Pap tests and raises the 
issue of having a Pap test. 
 
About this GP: 
This GP is  
your regular GP who you 
usually see for most care, 
including Pap tests 
This GP is   male 
This GP’s practice will receive a special incentive 




About the tests available: 
  Standard Pap 
test 
Liquid based 
Pap test  
The out of pocket costs to you for this test will be  $10  $40 
The chance that this test will give you a false 
negative result is   1 in 10  1 in 20 
The chance that this test will give you a false positive 
result is  1 in 150  1 in 250 
 
Other information the GP gives you about cervical screening: 
The GP tells you that you had your last Pap test  about 3 years ago 
The national recommendation is that women should 
have a Pap test   every 2 years 
If you have either Pap test, you can at the same time 
have an HPV test, at an additional out-of-pocket cost 
to you of  
 
$50 
The GP recommends that   you have the standard Pap test 
The GP recommends that you   do not have the HPV test 
 
At this visit to the GP what would you choose to do? 
Circle the number next to your choice 
I would not have a cervical cancer screening test 
 
I would have a standard Pap test 
 







Circle Yes or No to show your choice 
 
If you chose to have a Pap test, would you also have the HPV test at 








Appendix A (cont’) 
 
The following information was given randomly to only half of the respondents in the 
follow-up DCE (DCE2) 
 
 
What is HPV? Human Papillomavirus (HPV) is a sexually transmitted infection commonly 
affecting both men and women. Almost all abnormal Pap smear results are caused by HPV. 
However, in 98% of cases, HPV infection clears by itself. In rare cases, if the virus persists 
and is left undetected, it can lead to cervical cancer. This usually takes about 10 years. 
Although there are many strains of HPV, only a few cause cancer. Strains 16 and 18 cause 
about 70% of all cervical cancers. 
 
One vaccine (GARDASIL) has been approved for use in Australia. GARDASIL prevents 
infection from strains 16 and 18 if individuals are vaccinated before they are infected with 
them. It is a preventive measure and will not treat existing HPV infections. GARDASIL is 
given as a series of three injections over a period of seven months. The Australian 
Government has decided to fund GARDASIL under the National Immunization Program 
for girls and women aged 12-26, so this vaccine will be available free of charge for these 
age groups.  
 
Commencing in 2007, girls aged 12 and 13 will be vaccinated at school. Girls who are aged 
13-18 in 2007 will be vaccinated in a catch-up program. Women aged up to and including 
age 26 will be vaccinated in a community-based program, generally through GPs. The 
vaccine will be provided free but if a GP provides the vaccine, there could be a charge for 
the GP consultation.  
 
Sexually active women up to and including 26 years who are vaccinated will, overall, 
derive less protection than when the vaccine is given before sexual activity commences. 
Being vaccinated does not mean that women will be able to stop having Pap tests because 
HPV vaccination does not protect against all HPV types and will not stop all cases of 
cervical cancer or pre-cancerous cervical lesions.  
 
While the HPV test can give information about whether a woman has been infected by the 
human papilloma virus, it does not, in general give information about which particular 
strain of HPV is involved, so cannot help in deciding whether GARDASIL will provide 
protection for an individual woman. The best indicator of whether GARDASIL is likely to 








Appendix B1: Summary statistics (percent of the sample) 
  DCE1 DCE2 
 
 All  No 
Prior  Prior Uninformed Informed  Prior, 
Informed 
Age (sample mean)  41.85 36.12 35.96 36.29  36.14  35.72  38.15 
Education            
Secondary  or  lower  0.54 0.44 0.51 0.36  0.50  0.53  0.42 
Trade  certificates  0.16 0.18 0.18 0.18  0.23  0.12  0.23 
Some  university  0.10 0.12 0.12 0.13  0.09  0.15  0.07 
Completed  university  0.20 0.26 0.19 0.33  0.18  0.20  0.28 
Country of birth            
Not  Australia  0.14 0.21 0.26 0.17  0.20  0.32  0.16 
Income            
<=$50,000  0.63 0.47 0.58 0.37  0.57  0.59  0.42 
$50,000  -  $80,000  0.16 0.26 0.26 0.26  0.30  0.21  0.23 
>$80,000  0.14 0.24 0.15 0.33  0.11  0.21  0.30 
Missing  0.07 0.03 0.01 0.04  0.02  0.00  0.05 
Smoking             
Never  0.54 0.58 0.54 0.62  0.57  0.50  0.58 
Current  smoker  0.23 0.25 0.26 0.25  0.25  0.26  0.28 
Ex-smoker  0.23 0.17 0.20 0.13  0.18  0.24  0.14 
HPV-related              
Heard of HPV test    0.32    0.63      0.70 
Heard of HPV vaccine    0.39    0.79      0.86 
Recommended to HPV test    0.06    0.12      0.12 
Recommended to HPV vaccine    0.02    0.04      0.05 
            












Appendix B2: Choice distribution by age and income groups 



























Choice: No Test  Choice: Standard Pap only
Figure 3c: Case 3  Figure 3d: Case 4
































Choice: Liquid-based Pap only  Choice: Pap test & HPV test
Note: Each bar represents the sample mean of women in a given age group choosing the specific test option. 
The first row (yellow bars) is based on DCE1 sample and the second row (blue bars) represents the case for 




Note: each bar represents the sample mean of women in a given income group choosing the specific test option. The 
first row (yellow bars) is based on DCE1 sample and the second row (blue bars) represents the case for all women 
DCE2. 




























Choice: No Test  Choice: Standard Pap only
Figure 3c: Case 3  Figure 3d: Case 4
Choice: Liquid-based Pap only  Choice: Pap test & HPV test
































Appendix C1: MXL results – Case 2 
   No prior  Prior    No Prior  Prior 
   Coeff.  p  Coeff.  p    Coeff.  p  Coeff.  p 
Socio-demographics         Alt-spec: Pap test       
          Cost:  A+$20  0.282  0.000 0.253 0.000 
Age  0.034 0.003 -0.008 0.589  Cost:  A+$30    0.009 0.890  0.056  0.384 
Trade  certificates  0.752  0.085 1.101 0.081  Cost:  A+$40  -0.489  0.000  -0.409  0.000 
Some university  1.056  0.029  0.999  0.073  Cost: A+$10   0.197    0.100   
Completed university  0.726  0.141  0.552  0.270  FP: 1/250, 1/500  0.146  0.029  0.083  0.203 
Inc $50 - $80,000
 a  -0.286  0.480 -1.711 0.000  FP:  1/150,  1/150  -0.112 0.100  -0.006  0.925 
Inc >$80,000
a  0.893 0.063 -0.479 0.344  FP:  1/100,  1/100  -0.280 0.000  -0.357  0.000 
Inc missing
 a      -0.973  0.349  FP: 1/1000, 1/2000   0.247    0.281   
Not born in Australia  0.618  0.107  0.798  0.122  FN: 1/15, 1/33  0.053  0.429  0.029  0.653 
Current smoker  1.471  0.000  -0.164  0.756  FN: 1/10, 1/20   0.060  0.367  0.051  0.430 
Ex-smoker  1.145 0.022 -0.300 0.610  FN:  1/5,  1/10  -0.321 0.000  -0.274  0.000 
Common          FN:  1/20,  1/100 0.207    0.194   
Interval:  1  year  0.752  0.000 0.879 0.000  Alt-spec: HPV test       
Interval: 3 years  -0.177  0.084  -0.094  0.372  Rec: HPV test  0.547  0.000  0.498  0.000 
Interval: 5 years  -0.909  0.000  -1.150  0.000  Rec: no HPV test  -0.547   -0.498   
Interval: 2 years  0.334    0.365    HPV cost: $100  0.080  0.500  -0.058  0.601 
Last screen: 2 years  -0.234  0.017  -0.173  0.091  HPV cost: $150  -0.547  0.000  -0.541  0.000 
Last screen: 3 years  0.443  0.000  0.369  0.000  HPV cost: $200  -0.821  0.000  -0.596  0.000 
Last screen: 5 years  1.047  0.000  1.166  0.000  HPV cost: $50  1.288    1.196   
Last screen: 1 year  -1.255    -1.362    Intercepts (ASCs)       
GP:  new  -0.561  0.000 -0.660 0.000  P  -3.159 0.000  -1.065  0.128 
GP: seen before  0.561    0.660    Std. dev  2.023  0.000  2.434  0.000 
GP:  male  -0.718  0.000 -0.692 0.000  L  -4.196 0.000  -1.070  0.111 
GP: female  0.718    0.692    Std. dev  1.831  0.000  2.103  0.000 
Rec:  standard  0.425  0.000 0.567 0.000  PH  -4.549 0.000  -1.781  0.011 
Rec:  liquid-based  0.190  0.053 0.177 0.083  Std.  dev  3.116 0.000  2.770  0.000 
Rec: any Pap  0.339  0.001  0.331  0.001  LH  -5.016 0.000  -1.288  0.056 
Rec: no test  -0.955    -1.075    Std. dev  3.301  0.000  2.803  0.000 
GP: get finc incentive  0.112  0.052  0.002  0.980  Correlation*       
GP: no finc incentive  -0.112    -0.002    P, L  0.405  0.005 0.775 0.000 
         P, PH  0.520  0.000 0.308 0.001 
         P, LH  -0.091 0.184 0.070 0.266 
         L, PH  0.281  0.025 0.355 0.000 
         L, LH  0.423  0.002 0.429 0.000 
         PH, LH  0.703  0.000 0.834 0.000 
                
          N 12,220    12,135   
            Log L  -2,314    -2,344   
Note: 
a for No prior sample, the reference group is women with income less than $50,000 and a woman 
with missing income information. The woman with missing income is aged 15 – 20 years old. For Prior 
sample, the reference group is women with income less than $50,000. Those with missing income 
information are classified as separate category. The number of replication for simulated probabilities 
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   Uninformed  Informed    Uninformed  Informed 
    Coeff.  p  Coeff. p    Coeff. p Coeff. p 
Socio-demographics        Alt-spec: Pap test      
Age  -0.001 0.931  0.013 0.312  Cost:  A+$20  0.206 0.023 0.381 0.000 
Trade certificates  0.869  0.191  -0.576  0.362  Cost: A+$30   0.061  0.496  -0.047  0.644 
Some university  -2.104  0.019  2.328  0.000  Cost: A+$40  -0.417  0.000  -0.580  0.000 
Completed university  -0.918  0.216  0.975  0.058  Cost: A+$10   0.150    0.246   
Inc $50 - $80,000 
a  0.412 0.421 0.394  0.382  FP:  1/250,  1/500  0.157  0.081 0.135 0.178 
Inc >$80,000 
a  0.475 0.597 0.620  0.235  FP:  1/150,  1/150  -0.181  0.052  -0.036  0.721 
Not born in Australia  2.304  0.007  -0.149  0.731  FP: 1/100, 1/100  -0.188  0.039  -0.405  0.000 
Current smoker  0.458  0.479  0.842  0.077  FP: 1/1000, 1/2000   0.212    0.306   
Ex-smoker  2.069 0.005 0.762  0.122  FN:  1/15,  1/33  0.071  0.432 0.039 0.703 
Common         FN:  1/10,  1/20   0.001  0.989  0.127  0.203 
Interval: 1 year  0.794  0.000  0.720  0.000  FN: 1/5, 1/10  -0.279  0.003  -0.378  0.000 
Interval:  3  years  -0.133 0.356 -0.251  0.091  FN:  1/20,  1/100  0.207    0.212   
Interval:  5  years  -1.047 0.000 -0.753  0.000  Alt-spec: HPV test      
Interval: 2 years  0.386    0.284    Rec: HPV test  0.592  0.000  0.477  0.000 
Last screen: 2 years   -0.332  0.015  -0.144  0.318  Rec: no HPV test  -0.592  -0.477  
Last screen: 3 years   0.488  0.000  0.385  0.009  HPV cost: $100  0.155  0.298  -0.017  0.930 
Last screen: 5 years   1.144  0.000  0.976  0.000  HPV cost: $150  -0.475  0.003  -0.676  0.002 
Last screen: 1 year   -1.300    -1.217    HPV cost: $200  -0.793  0.000  -0.885  0.000 
GP: new  -0.554  0.000  -0.583  0.000  HPV cost: $50  1.113    1.579   
GP: seen before  0.554    0.583    Intercepts (ASCs)      
GP:  male  -0.904 0.000 -0.522  0.000  P  -0.812 0.373 -2.095 0.004 
GP: female  0.904    0.522    Std. dev  2.600  0.000  1.090  0.005 
Rec:  standard  0.384 0.005 0.465  0.001  L  -2.636 0.004 -3.766 0.000 
Rec:  liquid-based  0.168 0.217 0.233  0.105  Std.  dev  1.988  0.002 2.101 0.001 
Rec: any Pap  0.356  0.009  0.331  0.020  PH  -2.630 0.008 -4.373 0.000 
Rec: no test  0.907    1.030    Std. dev  2.362  0.000  3.111  0.010 
GP: get finc incentive  0.111  0.165  0.108  0.195  LH  -4.098 0.000 -5.063 0.000 
GP: no finc incentive  -0.111    -0.108    Std. dev  2.479  0.000  2.418  0.020 
        Correlation*      
        P, L  0.718 0.008 0.275 0.080 
        P, PH  0.438 0.012 0.222 0.051 
        P, LH  -0.223 0.037 -0.208 0.129 
        L, PH  0.405 0.019 -0.140 0.374 
        L, LH  0.320 0.024 0.180 0.545 
        PH, LH  0.551 0.001 0.799 0.013 
               
        N  6,955    5,265   
         Log  L  -1,287    -988   
Note: 
a for Uninformed sample, the reference group is women with income less than $50,000 and a 
woman with missing income information. The woman with missing income is aged 15 – 20 years 
old. For Informed sample, all women have income information. The number of replication for 





Appendix C3: MXL results – Case 4 
   DCE1  Prior Informed    DCE1  Prior Informed 
   Coeff.  p  Coeff.  p    Coeff. p Coeff.  p 
41 
  
Socio-demographics        Alt-spec: Pap test       
Age  0.005 0.620 0.029  0.073  Cost:  A+$20  0.318 0.000 0.314  0.000 
Trade certificates  -0.222  0.618  1.467  0.011  Cost: A+$30   0.060  0.189  -0.002  0.986 
Some  university  -0.525 0.173 -1.819  0.071  Cost:  A+$40  -0.418 0.000 -0.450  0.000 
Completed university  0.160  0.658  0.434  0.548  Cost: A+$10   0.041    0.138   
Inc $50 - $80,000  0.342  0.343  -2.474  0.000  FP: 1/250, 1/500  0.021  0.652  0.141  0.104 
Inc >$80,000  0.243  0.511  -2.610  0.000  FP: 1/150, 1/150  -0.029  0.524  -0.003  0.974 
Inc  missing  -0.972 0.036 -1.939  0.193  FP:  1/100,  1/100  -0.205 0.000 -0.356  0.000 
Not born in Australia  0.075  0.853  -0.137  0.878  FP: 1/1000, 1/2000   0.214    0.218   
Current  smoker  -0.452 0.182 -0.970  0.053  FN:  1/15,  1/33  0.024 0.590 0.110 0.205 
Ex-smoker  -0.114  0.762  1.753  0.042  FN: 1/10, 1/20   0.028  0.533  -0.031  0.728 
Common         FN:  1/5,  1/10  -0.239  0.000  -0.194  0.030 
Interval:  1  year  0.715 0.000 0.825  0.000  FN:  1/20,  1/100         
Interval:  3  years  -0.127 0.062 -0.010  0.942  Alt-spec: HPV test       
Interval: 5 years  -0.858  0.000  -0.924  0.000  Rec: HPV test  0.571  0.000  0.538  0.000 
Interval: 2 years  0.270    0.109    Rec: no HPV test  -0.571  -0.538   
Last screen: 2 years   -0.061  0.374  0.011  0.935  HPV cost: $100  -0.028  0.719  -0.119  0.470 
Last screen: 3 years   0.295  0.000  0.235  0.086  HPV cost: $150  -0.411  0.000  -0.635  0.000 
Last screen: 5 years   0.951  0.000  1.076  0.000  HPV cost: $200  -0.784  0.000  -0.473  0.007 
Last screen: 1 year   -1.185    -1.322    HPV cost: $50  1.223    1.227   
GP:  new  -0.522 0.000 -0.822  0.000  Intercepts (ASCs)       
GP: seen before  0.522    0.822    P  -0.445 0.414 -1.319  0.058 
GP:  male  -0.469 0.000 -0.617  0.000  Std.  dev  2.671 0.000 2.328 0.000 
GP: female  0.469    0.617    L  -1.331 0.014 -1.450  0.031 
Rec:  standard  0.540 0.000 0.449  0.001  Std.  dev  2.481 0.000 1.581  0.000 
Rec:  liquid-based  0.067 0.318 0.290  0.036  PH  -2.299 0.000 -2.522  0.000 
Rec:  any  Pap  0.365 0.000 0.243  0.070  Std.  dev  2.943 0.000 3.165  0.000 
Rec: no test  -0.972    -0.982    LH  -2.541 0.000 -2.078  0.004 
GP: get finc incentive  -0.049  0.215  -0.039  0.621  Std. dev  3.975  0.000  3.534  0.000 
GP: no finc incentive  0.049    0.039    Correlation*       
        P, L  0.498 0.000 0.668  0.001 
        P, PH  0.507 0.000 0.375  0.001 
        P, LH  0.057 0.115 0.100  0.172 
        L, PH  0.558 0.000 0.396  0.000 
        L, LH  0.765 0.000 0.425  0.000 
        PH, LH  0.675 0.000 0.909  0.000 
               
        N 26,720    6,865  
          Log L  -5,158    -1,241   








Appendix C4: MXL result – restricted sample of women over 30 years old  
  Restricted DCE1  Restricted DCE2    Restricted DCE1  Restricted DCE2 
   Coeff. p Coeff. p    Coeff. p Coeff. p 





Age  0.034 0.035 -0.040 0.036  Cost:  A+$20  0.375 0.000 0.308 0.000 
Trade certificates  0.214 0.682 0.249 0.606  Cost:  A+$30    0.074 0.166 -0.053 0.428 
Some university  0.503 0.249 0.279 0.696  Cost:  A+$40  -0.478 0.000 -0.436 0.000 
Completed university  0.599 0.214 0.425 0.410  Cost:  A+$10    0.029    0.180   
Inc $50 - $80,000  0.095 0.819 -0.280 0.554 FP:  1/250,  1/500  -0.012 0.826 0.183 0.005 
Inc >$80,000  0.473 0.277 -0.783 0.157 FP:  1/150,  1/150  -0.002 0.971 -0.071 0.288 
Inc missing  -1.651 0.001 0.179 0.837 FP:  1/100,  1/100  -0.225 0.000 -0.364 0.000 
Not born in Australia  -0.415  0.246  0.487  0.257  FP: 1/1000, 1/2000   0.238    0.251   
Current smoker  -0.049 0.927 0.110 0.840  FN:  1/15,  1/33  0.037 0.487 0.059 0.369 
Ex-smoker  -0.367 0.339 1.743 0.000  FN:  1/10,  1/20    0.033 0.532 0.038 0.565 
Common        FN:  1/5,  1/10 -0.247  0.000  -0.293  0.000 
Interval: 1 year  0.754 0.000 0.851 0.000  FN:  1/20,  1/100  0.177    0.196   
Interval: 3 years  -0.095 0.234 -0.085 0.417 Alt-spec: HPV test      
Interval: 5 years  -0.969 0.000 -1.092 0.000 Rec:  HPV  test  0.527 0.000 0.537 0.000 
Interval: 2 years  0.309    0.326    Rec: no HPV test  -0.527  -0.537  
Last screen: 2 years   -0.060 0.449 -0.285 0.005 HPV  cost:  $100  -0.051 0.581 -0.053 0.664 
Last screen: 3 years   0.308 0.000 0.445 0.000  HPV  cost:  $150  -0.473 0.000 -0.558 0.000 
Last screen: 5 years   1.038 0.000 1.340 0.000  HPV  cost:  $200  -0.838 0.000 -0.497 0.000 
Last screen: 1 year   -1.286  -1.501  HPV  cost:  $50  1.362  1.108  
GP: new  -0.568 0.000 -0.702 0.000 Intercepts (ASCs)      
GP: seen before  0.568  0.702   P  -1.936 0.079 0.717 0.436 
GP: male  -0.414 0.000 -0.734 0.000 Std.  dev  2.880 0.000 3.083 0.000 
GP: female  0.414  0.734   L  -2.204 0.044 0.314 0.735 
Rec: standard  0.505 0.000 0.436 0.000  Std.  dev  2.865 0.000 2.408 0.000 
Rec: liquid-based  0.038 0.633 0.139 0.173  PH  -3.674 0.001 -1.025 0.297 
Rec: any Pap  0.354 0.000 0.264 0.009  Std.  dev  3.030 0.000 3.389 0.000 
Rec: no test  -0.897  -0.838  LH  -3.143 0.003 -0.859 0.359 
GP: get finc incentive  -0.070 0.127 0.046 0.441  Std.  dev  5.118 0.000 3.647 0.000 
GP: no finc incentive  0.070  -0.046  Correlation*      
       P, L  0.432 0.000 0.526 0.000 
       P, PH  0.473 0.000 0.421 0.000 
       P, LH  -0.074 0.018 -0.179 0.004 
       L, PH  0.459 0.000 0.570 0.000 
       L, LH  0.728 0.000 0.521 0.000 
       PH, LH  0.598 0.000 0.732 0.000 
             
       N  20,160    12,940   
       Log  L  -3,691  -2,301  
Note: The number of replication for simulated probabilities are R=1000. * p-values based on 
covariance terms. Only 25 percent of DCE1 sample are aged less than 30. The number of women in the 
restricted sample is 81. Results for unrestricted case DCE2 are reported in Table 4.  
 
 